SallyJohnson United KingdomNational Renal Complement Therapeutics Centre, Newcastle Upon Tyne Hospitals NHS Foundation Trust, United Kingdom

SallyJohnson
Dr Sally Johnson is the lead paediatric clinician at the UK National Renal Complement Therapeutics Centre, which has a national role in the management of patients with atypical HUS and C3G. She is also a paediatric nephrologist at the Great North Children’s Hospital, UK. She undertook clinical and academic training in the West Midlands, including a PhD in aHUS. She was Chief Investigator of The National Study of MPGN and C3G and of the ECUSTEC trial, a randomised controlled trial of Eculizumab in STEC-HUS. She was Research Secretary for the British Association for Paediatric Nephrology (BAPN) from 2019 to 2022 and is co-chair of the BAPN Clinical Studies Group. She is a member of the Kidney Research UK (KRUK) grants committee.
Institution

Day 3 - Tuesday April 16, 2024

Time Session
12:30 p.m.
1:30 p.m.
New Insights into C3 Glomerulonephritis: Focus on Pathogenesis and Potential Therapeutic Targets
SK1003
AnujaJava Chairperson United StatesWASHINGTON UNIVERSITY SCHOOL OF MEDICINE IN ST. LOUIS
LizLightstone Chairperson United KingdomImperial College London
  • Complement in Kidney Disease: Overview of the Complement Cascade in Kidney Injury
    Peter Zipfel Speaker Peter.Zipfel@hki-jena.deGermanyLeibniz Institute for Natural Product Research and Infection Biology
  • C3 Glomerulopathy: New Developments and Therapeutic Targets
    CarlaNester Speaker carla-nester@uiowa.eduUnited StatesUniversity of Iowa
  • Challenges in Diagnosing C3G
    SallyJohnson Speaker sallyajohnson73@gmail.comUnited KingdomNational Renal Complement Therapeutics Centre, Newcastle Upon Tyne Hospitals NHS Foundation Trust, United Kingdom
  • Q and A
Hall C1